SI0959888T1 - Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease - Google Patents

Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease

Info

Publication number
SI0959888T1
SI0959888T1 SI9730230T SI9730230T SI0959888T1 SI 0959888 T1 SI0959888 T1 SI 0959888T1 SI 9730230 T SI9730230 T SI 9730230T SI 9730230 T SI9730230 T SI 9730230T SI 0959888 T1 SI0959888 T1 SI 0959888T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical composition
alzheimer
disease
manufacture
treatment
Prior art date
Application number
SI9730230T
Other languages
English (en)
Slovenian (sl)
Inventor
Panayotis Nikolas Gerolymatos
Original Assignee
P. N. Gerolymatos S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by P. N. Gerolymatos S.A. filed Critical P. N. Gerolymatos S.A.
Publication of SI0959888T1 publication Critical patent/SI0959888T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI9730230T 1996-08-13 1997-08-08 Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease SI0959888T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR96100286 1996-08-13
PCT/IB1997/000983 WO1998006403A1 (en) 1996-08-13 1997-08-08 Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
EP97932969A EP0959888B1 (en) 1996-08-13 1997-08-08 Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
SI0959888T1 true SI0959888T1 (en) 2002-10-31

Family

ID=10942479

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730230T SI0959888T1 (en) 1996-08-13 1997-08-08 Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease

Country Status (26)

Country Link
US (1) US6001852A (ru)
EP (1) EP0959888B1 (ru)
JP (1) JP2000516606A (ru)
KR (1) KR100489969B1 (ru)
CN (1) CN1114407C (ru)
AT (1) ATE205086T1 (ru)
AU (1) AU720643B2 (ru)
BR (1) BR9711194A (ru)
CA (1) CA2264097C (ru)
CZ (2) CZ295118B6 (ru)
DE (1) DE69706566T2 (ru)
DK (1) DK0959888T3 (ru)
ES (1) ES2162319T3 (ru)
HK (1) HK1022437A1 (ru)
HU (1) HUP9903906A3 (ru)
IL (1) IL128416A (ru)
IS (1) IS1907B (ru)
NO (1) NO316768B1 (ru)
NZ (1) NZ334124A (ru)
PL (1) PL188838B1 (ru)
PT (1) PT959888E (ru)
RU (1) RU2193406C2 (ru)
SI (1) SI0959888T1 (ru)
SK (1) SK283117B6 (ru)
TR (1) TR199900293T2 (ru)
WO (1) WO1998006403A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
EA002526B1 (ru) * 1997-08-21 2002-06-27 П.Н.Геролиматос С.А. Применение фанхинона для лечения болезни альцгеймера
ATE555780T1 (de) * 1997-10-24 2012-05-15 John P Blass Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
DK1140090T3 (da) 1999-01-07 2005-04-18 Gerolymatos P N Sa Anvendelse af phanquinon til behandlingen eller hindringen af hukommelsessvigt
US6692234B2 (en) 1999-03-22 2004-02-17 Water Management Systems Pump system with vacuum source
AU2001230584A1 (en) * 2000-02-09 2001-08-20 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
US6803379B2 (en) * 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US7692011B2 (en) 2002-10-04 2010-04-06 Prana Biotechnology Limited 8-hydroxy and 8-mercapto quinazolinones
US20080063599A1 (en) * 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
EP1617844A4 (en) * 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
JP2007511544A (ja) * 2003-11-19 2007-05-10 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド アミロイド症の予防若しくは治療のための組成物および方法
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
TWI319708B (en) * 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
KR20080090408A (ko) * 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Aβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
CN102225930A (zh) * 2006-04-14 2011-10-26 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性(amd)的方法
TWI551607B (zh) * 2006-07-14 2016-10-01 Ac免疫公司 人類化抗體
SI2468770T1 (en) * 2006-07-14 2018-05-31 Ac Immune S.A. A humanized antibody against amyloid beta.
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
ES2332687B1 (es) * 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
FR2966827B1 (fr) 2010-10-27 2014-08-22 Kimonella Ventures Ltd Compose peptidique utile pour l'inhibition de la formation de plaques amyloides
JP6153179B2 (ja) * 2013-04-02 2017-06-28 アンジー ファーマスーティカル シーオー.,エルティーディー.Annji Pharmaceutical Co., Ltd. 抗神経変性剤としての多機能キノリン誘導体
EP4039255A1 (en) 2014-04-24 2022-08-10 Omoidesouzou Co. Ltd. Amyloid fiber formation limiter or inhibitor
KR20160057500A (ko) * 2014-11-05 2016-05-24 아카데미아 시니카 클리오퀴놀을 포함하는 자폐증 스펙트럼 장애의 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174899A (en) * 1960-12-30 1965-03-23 Ciba Geigy Corp Composition for the management of post antibiotic enteritis
US3178343A (en) * 1962-11-27 1965-04-13 Ciba Geigy Corp Pharmaceutical compositions and method of using same
DE1617417A1 (de) * 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
DE3932338A1 (de) * 1989-09-28 1991-04-11 Nmi Naturwissenschaftl U Mediz Verfahren zur praeventiven therapie von morbus alzheimer
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
GB9108080D0 (en) * 1991-04-15 1991-06-05 Smithkline Beecham Plc Pharmaceutical composition
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
JP3277211B2 (ja) * 1991-11-12 2002-04-22 プラナ・バイオテクノロジー・リミテッド アルツハイマー病の試験方法と治療方法
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
AU1831195A (en) * 1994-01-13 1995-08-01 Research Foundation For Mental Hygiene, Inc. Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
EP0713392A1 (en) * 1994-05-11 1996-05-29 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including h. pylori, infections and related diseases
US5505958A (en) * 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture

Also Published As

Publication number Publication date
ATE205086T1 (de) 2001-09-15
US6001852A (en) 1999-12-14
KR20000029958A (ko) 2000-05-25
CZ295118B6 (cs) 2005-05-18
HUP9903906A2 (hu) 2000-04-28
PL188838B1 (pl) 2005-04-29
HUP9903906A3 (en) 2001-01-29
NZ334124A (en) 2000-10-27
RU2193406C2 (ru) 2002-11-27
EP0959888A1 (en) 1999-12-01
CZ48499A3 (cs) 1999-07-14
CZ292411B6 (cs) 2003-09-17
NO990595L (no) 1999-04-12
SK17999A3 (en) 1999-09-10
CA2264097C (en) 2007-11-27
AU3632497A (en) 1998-03-06
KR100489969B1 (ko) 2005-05-17
AU720643B2 (en) 2000-06-08
DK0959888T3 (da) 2001-11-05
CN1114407C (zh) 2003-07-16
IS4972A (is) 1999-02-10
TR199900293T2 (xx) 1999-06-21
CA2264097A1 (en) 1998-02-19
IS1907B (is) 2003-12-16
NO990595D0 (no) 1999-02-09
BR9711194A (pt) 2000-01-11
CN1230115A (zh) 1999-09-29
PL331822A1 (en) 1999-08-02
HK1022437A1 (en) 2000-08-11
ES2162319T3 (es) 2001-12-16
EP0959888B1 (en) 2001-09-05
WO1998006403A1 (en) 1998-02-19
DE69706566T2 (de) 2002-07-11
IL128416A0 (en) 2000-01-31
PT959888E (pt) 2002-02-28
NO316768B1 (no) 1999-04-12
SK283117B6 (sk) 2003-02-04
JP2000516606A (ja) 2000-12-12
IL128416A (en) 2004-06-01
DE69706566D1 (de) 2001-10-11

Similar Documents

Publication Publication Date Title
HK1022437A1 (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
GB9103764D0 (en) Compositions
IL134263A0 (en) Use of phanquinone for the treatment of alzheimer's disease
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
DK0583026T3 (ru)
BG102667A (en) Diosgenine-containing composition
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
AUPP823999A0 (en) A treatment
UA29461C2 (ru) Средство для лечения амилоидоза, способ лечения амилоидоза
HUP9802536A3 (en) Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer
NZ268039A (en) Use of efaroxan in treating parkinson's disease
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.